Given these trial results and extrapolation from cervical cancer data, pembrolizumab is FDA approved and current NCCN guidelines endorse pembrolizumab for second-line therapy for TMB-H, PD-L1 positive, or MSI-high/dMMR tumors [167]. The gene discussed is CD274; the disease is cervical cancer.